Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines

Epidermal growth factor receptor (EGFR) is a well-validated oncological target molecule for monoclonal antibody therapies and Sym004 is a novel anti-EGFR antibody mixture comprising two recombinant chimeric IgG1 antibodies against non-overlapping epitopes of EGFR. Because EGFR is highly expressed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuoka, Shota, Kojima, Takashi, Koga, Yoshikatsu, Yamauchi, Mayumi, Komatsu, Masayuki, Komatsuzaki, Rie, Sasaki, Hiroki, Yasunaga, Masahiro, Matsumura, Yasuhiro, Doi, Toshihiko, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355242/
https://www.ncbi.nlm.nih.gov/pubmed/28038457
http://dx.doi.org/10.18632/oncotarget.14209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355242/
https://www.ncbi.nlm.nih.gov/pubmed/28038457
http://dx.doi.org/10.18632/oncotarget.14209

Ejemplares similares